HK$ 126.6
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and solid tumors; and...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overvalued on P/FCF.
Target Price
The average target price of 9926.HK is 175 and suggests 38% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
